Target Organs and Levels of Evidence for TR-538
Toxicology and Carcinogenesis Studies of Methyl Isobutyl Ketone (CASRN 108-10-1) in F344/N Rats and B6C3F1 Mice (Inhalation Studies)
Chemical (Study Title)
CASRN | Peer Review Date | Primary Uses | Route/Exposure Levels | Study Laboratory |
|---|
Methyl isobutyl ketone
108-10-1 | 09/27/2005 | Used as a denaturant for rubbing alcohol; as a solvent for paints, varnishes, nitrocellulose, lacquers, and protective coatings; in industrial extraction processes; in dry-cleaning preparations; and in the synthesis of methyl isobutyl carbinol. Associated with tobacco: reported either as a natural component of tobacco, pyrolysis product (in tobacco smoke), or additive for one or more types of tobacco products. | Inhalation
R&M: 0, 450, 900, OR 1800 PPM | Battelle Northwest Laboratory |
Levels of Evidence
Male Rats: Some Evidence
| Type | Organ/Tissue (Lesion) |
|---|
| Neoplastic Lesions | - Kidney Tubular Cell:
ADENOMA (STANDARD EVALUATION - 0/50 0/50 2/50 3/50; STANDARD AND EXTENDED EVAULATION COMBINED - 2/50 3/50 3/50 10/50); CARCINOMA (STANDARD EVALUATION - 0/50 1/50 0/50 2/50); ADENOMA OR CARCINOMA (COMBINED) (STANDARD EVAULATION - 0/50 1/50 2/50 4/50; STANDARD AND EXTENDED EVALUATION - 2/50 4/50 3/50 11/50)
|
| May Have Been Related | - Hematopoietic System:
MONONUCLEAR CELL LEUKEMIA 25/50 26/50 32/50 35/50
|
| Non-Neoplastic Lesions | - KIDNEY: TUBULE HYPERPLASIA; INCREASED SEVERITY OF NEPHROPATHY; PELVIS TRANSITIONAL EPITHELIAL HYPERPLASIA; PAPILLA MINERALIZATION
- ADRENAL GLAND: ADRENAL MEDULLA HYPERPLASIA
|
Female Rats: Equivocal Evidence
| Type | Organ/Tissue (Lesion) |
|---|
| Neoplastic Lesions | - Kidney Mesenchymal Cell:
TUMOR MALIGNANT 0/50 0/50 0/50 2/50
|
| Non-Neoplastic Lesions | |
Male Mice: Some Evidence
| Type | Organ/Tissue (Lesion) |
|---|
| Neoplastic Lesions | - Liver:
ADENOMA 17/50 25/50 23/50 34/50 ADENOMA OR CARCINOMA (COMBINED) 27/50 34/50 28/50 37/50
|
Female Mice: Some Evidence
| Type | Organ/Tissue (Lesion) |
|---|
| Neoplastic Lesions | - Liver:
ADENOMA 13/50 15/50 20/50 23/50 ADENOMA OR CARCINOMA (COMBINED) 17/50 17/50 22/50 27/50
|
